Blinatumomab received accelerated United States Food and Drug Administration (US FDA) approval in 2014 based on results from the open label phase-2 clinical trial by Topp et al, which evaluated the drug in adult patients with R/R CD19-positive (+) Philadelphia (Ph)- negative B-ALL.21 Here, CD19 is linked to precursor B-cell acute lymphoblastic leukemia.